Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
31.65
-0.53 (-1.65%)
At close: Oct 2, 2026, 4:00 PM EDT
31.85
+0.20 (0.63%)
After-hours: Oct 2, 2026, 7:38 PM EDT
Celldex Therapeutics Revenue
Celldex Therapeutics had revenue of $22.00K in the quarter ending June 30, 2026, a decrease of -96.99%. This brings the company's revenue in the last twelve months to $158.00K, down -97.27% year-over-year. In the year 2025, Celldex Therapeutics had annual revenue of $1.55M, down -77.99%.
Revenue (ttm)
$158.00K
Revenue Growth
-97.27%
P/S Ratio
15,730.76
Revenue / Employee
$798
Employees
198
Market Cap
2.49B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.55M | -5.48M | -77.99% |
| Dec 31, 2024 | 7.02M | 137.00K | 1.99% |
| Dec 31, 2023 | 6.88M | 4.53M | 192.02% |
| Dec 31, 2022 | 2.36M | -2.29M | -49.32% |
| Dec 31, 2021 | 4.65M | -2.77M | -37.30% |
| Dec 31, 2020 | 7.42M | 3.85M | 107.61% |
| Dec 31, 2019 | 3.57M | -5.97M | -62.54% |
| Dec 31, 2018 | 9.54M | -3.21M | -25.15% |
| Dec 31, 2017 | 12.74M | 5.96M | 87.78% |
| Dec 31, 2016 | 6.79M | 1.31M | 23.83% |
| Dec 31, 2015 | 5.48M | 1.89M | 52.82% |
| Dec 31, 2014 | 3.59M | -525.00K | -12.77% |
| Dec 31, 2013 | 4.11M | -7.09M | -63.30% |
| Dec 31, 2012 | 11.20M | 1.94M | 20.91% |
| Dec 31, 2011 | 9.27M | -37.53M | -80.20% |
| Dec 31, 2010 | 46.79M | 31.61M | 208.25% |
| Dec 31, 2009 | 15.18M | 7.72M | 103.59% |
| Dec 31, 2008 | 7.46M | 6.05M | 430.30% |
| Dec 31, 2007 | 1.41M | 506.82K | 56.36% |
| Dec 31, 2006 | 899.18K | -2.19M | -70.88% |
| Dec 31, 2005 | 3.09M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Harmony Biosciences Holdings | 959.90M |
| ADMA Biologics | 512.28M |
| Zai Lab | 449.61M |
| Beam Therapeutics | 156.04M |
| Viridian Therapeutics | 71.13M |
| Recursion Pharmaceuticals | 54.86M |
| Nurix Therapeutics | 36.77M |
| NewAmsterdam Pharma Company | 7.12M |
CLDX News
- 1 day ago - Celldex adverse event concerns overblown, says H.C. Wainwright - TheFly
- 10 days ago - Celldex price target raised to $88 from $70 at Leerink - TheFly
- 10 days ago - Celldex price target raised to $57 from $50 at Morgan Stanley - TheFly
- 11 days ago - Celldex falls -11.4% - TheFly
- 11 days ago - Celldex price target raised to $64 from $42 at H.C. Wainwright - TheFly
- 11 days ago - Celldex falls -5.1% - TheFly
- 11 days ago - Celldex Therapeutics Transcript: Study result - Transcripts
- 11 days ago - Celldex Therapeutics Press release: Study result - Filings